Cargando…

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19

OBJECTIVE: This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 (‘Study 19’) to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic lateral sclerosis (ALS). METHODS: Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised item scor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Chalabi, Ammar, Chiò, Adriano, Merrill, Charlotte, Oster, Gerry, Bornheimer, Rebecca, Agnese, Wendy, Apple, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Neuromuscular
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841496/ https://www.ncbi.nlm.nih.gov/pubmed/33109706 http://dx.doi.org/10.1136/jnnp-2020-323271

Ejemplares similares

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
por: Dreger, Marie, et al.
Publicado: (2022)

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018)

Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?
por: Prell, Tino, et al.
Publicado: (2016)

Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
por: Paganoni, Sabrina, et al.
Publicado: (2022)

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
por: Kaji, Ryuji, et al.
Publicado: (2019)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis and cerebellum
por: Kabiljo, Renata, et al.
Publicado: (2022)

Imaging muscle as a potential biomarker of denervation in motor neuron disease
por: Jenkins, Thomas M, et al.
Publicado: (2018)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Untargeted metabolomics yields insight into ALS disease mechanisms
por: Goutman, Stephen A, et al.
Publicado: (2020)

What causes amyotrophic lateral sclerosis?
por: Martin, Sarah, et al.
Publicado: (2017)

Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B
por: Takahashi, Toshiaki, et al.
Publicado: (2013)

Whole-genome sequencing and the clinician: a tale of two cities
por: Foley, A Reghan, et al.
Publicado: (2014)

Autosomal dominant eccentric core disease caused by a heterozygous mutation in the MYH7 gene
por: Romero, Norma B, et al.
Publicado: (2014)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients
por: Querin, Giorgia, et al.
Publicado: (2016)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Classifying Adverse Events Following Lower Limb Orthopaedic Surgery in Children With Cerebral Palsy: Reliability of the Modified Clavien-Dindo System
por: Zhou, Leena, et al.
Publicado: (2018)

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
por: Strauss, Kevin A., et al.
Publicado: (2018)

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018)

Differentiating lower motor neuron syndromes
por: Garg, Nidhi, et al.
Publicado: (2017)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
por: Capodivento, Giovanna, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study
por: Verboon, Christine, et al.
Publicado: (2021)

IgG(1) pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
por: Fehmi, Janev, et al.
Publicado: (2021)

Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)
por: van Eijk, Ruben P A, et al.
Publicado: (2022)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Variability in Postoperative Immobilization and Rehabilitation Following Reconstructive Hip Surgery in Nonambulatory Children With Cerebral Palsy
por: Miller, Stacey D., et al.
Publicado: (2021)

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Charcot-Marie-Tooth disease type 2CC due to NEFH variants causes a progressive, non-length-dependent, motor-predominant phenotype
por: Pipis, Menelaos, et al.
Publicado: (2022)

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
por: Carroll, Antonia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qc901vke2ehokrt4pttehmclqa